News | July 12, 2007

Biotronik Completes Enrollment of DES Trial

July 13, 2007 - Biotronik announced that it recently completed the enrollment of the ProLimus I First-In-Man trial to test the safety and efficacy of its ProGenic Pimecrolimus eluting coronary stent system.
Sixty-one patients enrolled at 5 sites in Belgium and Germany for the trial that will test the safety and clinical performance of the ProGenic Pimecrolimus eluting stent. Participating patients have single de-novo coronary artery lesions and will include patients with two-vessel disease. Clinical follow-up is conducted at 30 days, 6 months, 12 months and annually up to 3 years. At the 6-month follow-up all patients will undergo coronary angiography and intravascular ultrasound (IVUS) evaluation.
The primary endpoint of ProLimus I is a composite of major adverse cardiac events (MACE) at 6-month follow-up. Secondary endpoints include target vessel revascularisation (TVR), in-stent and in-segment binary restenosis, and late lumen loss (in-stent and in-segment) as measured by angiography.
The Biotronik ProGenic stent is comprised of four innovative elements: The PRO-Kinetic Cobalt Chromium Stent System; the PROBIO silicon carbide passive stent coating as a protective layer that reduces metal ion release and promotes endothelialization; a bioresorbable Poly-L-Lactic Acid polymer drug carrier; and the next generation in vascular drug technologies, Pimecrolimus. Following implantation of the ProGenic stent, drug and polymer is completely absorbed, leaving PROBIO as a long-term safety feature.
If results are favorable, the company will start enrollment of a randomized trial with approximately 320 patients in the first quarter of 2008.

For more information: www.biotronik.com

Related Content

Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Sponsored Content | Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
Biosensors, BioFreedom drug-coated stent, LEADERS FREE II IDE trial, first patient, U.S. pivotal study
News | Stents Drug Eluting| March 03, 2017
Biosensors International Group Ltd. announced in February enrollment of the first patient in LEADERS FREE II, its new...
CeloNova Cobra Pzf stent
Technology | Stents| March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable| January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents| January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
EXCEL Trial, TCT 2016, drug-eluting stents, CABG, surgery left main heart disease, LMCAD

Gregg W. Stone, M.D., presenting the EXCEL data at TCT 2016 during a standing room only late-breaking trial session.

Feature | Stents| January 12, 2017 | Dave Fornell
The biggest news from the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting this past fall was the results
Overlay Init